Drugs / anti-BCMA/CD70 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06553898 | Aug 2024 → Jul 2026 overdue | nephrotic syndrome | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-BCMA/CD70 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06553898 ↗ |
| Action | Deplete | “CAR-T therapy is an adoptive cell therapy that uses genetic modification technology to reprogram T cells and eliminate target cells expressing disease-related antigens through...” NCT06553898 ↗ |
| Modality | Cell therapy | “CAR-T therapy is an adoptive cell therapy” NCT06553898 ↗ |